entertainment -WSS

entertainment

author：comprehensive 2025-10-04 04:00:03 - browse：18577

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Nobel honors Karikó and Weissman's enduring partnership

WSS

Fauci’s Covid grilling leads GOP to weigh foreign research rules

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Fauci’s Covid grilling leads GOP to weigh foreign research rules

As JPM 2024 winds down, some health tech firms project optimism

Risky weight loss products often used by teens globally, per study

Medicare innovation center doesn’t save money, experts say

entertainment

entertainment

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Nobel honors Karikó and Weissman's enduring partnership

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Risky weight loss products often used by teens globally, per study

Medicare proposal to cover medical devices draws a mixed reaction

Flu, Covid vaccination rates decline, new survey data show

Medicare proposal to cover medical devices draws a mixed reaction

Some top drug companies are starting to take action on climate

Trump demands the U.S. pay no more for drugs than other countries … again

Experts study whether long Covid risk adds up with each reinfection

focus

Nobel honors Karikó and Weissman's enduring partnership

Setback for rare diseases as Taysha Gene Therapies pulls back

European officials brace for rough respiratory virus season

6 solutions to address cancer drug shortages and others

Health and fitness trackers are measuring the wrong things

Doulas covered by Medicaid under New York's new plan

knowledge

hotspot

hotspot

hotspot